雾化布地奈德联合依替米星在慢性支气管炎急性加重期患者中的应用效果  

Application effect of nebulized Budesonide combined with Etimicin in patients with acute exacerbation of chronic bronchitis

作　　者：高盼[1] 杨冬明 李瑶 石金凤 GAO Pan;YANG Dongming;LI Yao;SHI Jinfeng(Department of Respiratory and Critical Care Medicine,Beijing Jingmei Group General Hospital,Beijing102300,China)

机构地区：[1]北京京煤集团总医院呼吸与危重症医学科,北京102300

出　　处：《中国当代医药》2022年第5期52-55,共4页China Modern Medicine

摘　　要：目的探讨雾化布地奈德联合依替米星在慢性支气管炎急性加重期患者中的应用效果。方法选取2018年3月至2021年3月北京京煤集团总医院收治的106例慢性支气管炎急性加重期患者作为研究对象,采用随机数字表法将其分为对照组(53例)和观察组(53例)。对照组采用依替米星治疗,观察组采用依替米星联合雾化布地奈德治疗。比较两组患者的症状积分、炎症因子、肺功能及安全性。结果治疗前,两组症状积分、炎症因子及肺功能比较,差异无统计学意义(P>0.05);治疗后,观察组症状积分低于对照组,降钙素原(PCT)、C-反应蛋白(CRP)水平低于对照组,用力肺活量占预计值百分比(FVC%pred)、第一秒用力呼气容积占比(FEV1%pred)及呼吸峰流速占比(PEF%pred)高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论雾化布地奈德联合依替米星治疗慢性支气管炎急性加重期患者可有效改善临床相关症状,缓解炎症反应,改善肺功能,且具有一定安全性。Objective To investigate the application effect of nebulized Budesonide combined with Etimicin in patients with acute exacerbation of chronic bronchitis.Methods A total of 106 patients with acute exacerbation of chronic bronchitis in Beijing Jingmei Group General Hospital from March 2018 to March 2021 were selected as the research objects,and they were divided into the control group(53 cases)and the observation group(53 cases).The control group was treated with Etimicin,and the observation group was treated with Etimicin combined with nebulized Budesonide.The symptom scores,inflammatory factors,lung function and safety of the two groups of patients were compared.Results Before treatment,there was no significant difference in symptom scores,inflammatory factors and pulmonary function between the two groups(P>0.05).After treatment,the symptom scores of the observation group were lower than those of the control group,the levels of procalcitonin(PCT)and C-reactive protein(CRP)were lower than those of the control group,the percentage of forced vital capacity to the predicted value(FVC%pred),the forced exhalation in the first second.The proportion of air volume(FEV1%pred)and the proportion of peak respiratory flow rate(PEF%pred)were higher than those in the control group,and the difference was statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Nebulized Budesonide combined with Etimicin in the treatment of patients with acute exacerbations of chronic bronchitis can effectively improve clinical symptoms,relieve inflammation,improve lung function,and has a certain degree of safety.

关 键 词：慢性支气管炎急性加重期 布地奈德 依替米星 症状积分 炎症因子 

分 类 号：R562.2[医药卫生—呼吸系统]